No abstract

No abstract

No abstract

No abstract

No abstract

No abstract

Background: Selpercatinib (LOXO-292), a highly selective and potent RET kinase inhibitor, demonstrated marked and durable antitumor activity in pts with RET fusion+ NSCLC in an ongoing phase 1/2 trial. We evaluated best responses to last prior therapy received before enrollment and to selpercatinib by last prior therapy subgroups.Methods: Pts with RET fusion+ NSCLC enrolled in the global, multicenter, LIBRETTO-001 trial (NCT03157128) received the recommended phase 2 selpercatinib dose (160 mg twice daily) after dose escalation. This analysis assessed outcomes by category of last systemic therapy received prior to enrollment. Efficacy was analyzed in the first 105 consecutively enrolled pts pretreated with platinum chemotherapy (primary analysis set [PAS]). Adverse events (AEs) were measured in all pretreated pts who received selpercatinib by data cutoff date of 16-Dec-2019. abstracts Annals of Oncology Volume 31 -Issue S4 -2020 S835

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.